Compare GLBS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | HOWL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 30.7M |
| IPO Year | 2010 | 2021 |
| Metric | GLBS | HOWL |
|---|---|---|
| Price | $1.98 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | 96.9K | ★ 307.1K |
| Earning Date | 03-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $20.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.53 |
| 52 Week High | $2.44 | $2.23 |
| Indicator | GLBS | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 56.02 |
| Support Level | $1.51 | $0.79 |
| Resistance Level | $2.23 | $1.03 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 27.87 | 41.46 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.